Evidence map›Paper›PMID 37104056›Full record

ArticleBlood advances2023

Estimated mortality rates of individuals with sickle cell disease in Brazil: real-world evidence.

Rodolfo Delfini Cançado, Fernando Ferreira Costa, Clarisse Lobo, Celina Borges Migliavaca, Maicon Falavigna, Homero C R Souza Filho, Carolina Tosin Bueno, Ana Cristina Silva-Pinto

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Rodolfo Delfini CançadoDepartment of Hematology/Oncology, Santa Casa Medical School of São Paulo, São Paulo, Brazil.ORCID 0000-0003-3269-3780
Fernando Ferreira CostaSchool of Medical Sciences, University of Campinas, Campinas, Brazil.ORCID 0000-0002-4632-572X
Clarisse LoboHematological State Institute "Arthur de Siqueira Cavalcanti" - HEMORIO, Rio de Janeiro, Brazil.ORCID 0000-0002-4262-5792
Celina Borges MigliavacaHTAnalyze Consultoria e Treinamento, Porto Alegre, Brazil.ORCID 0000-0003-1389-2311
Maicon FalavignaHTAnalyze Consultoria e Treinamento, Porto Alegre, Brazil.ORCID 0000-0002-2637-6837
Homero C R Souza FilhoDepartment of Hematology-Oncology, Novartis Oncology, São Paulo, Brazil.ORCID 0000-0001-9625-6673
Carolina Tosin BuenoDepartment of Hematology-Oncology, Novartis Oncology, São Paulo, Brazil.ORCID 0000-0001-9190-5339
Ana Cristina Silva-PintoDepartment of Medical Imaging, Hematology, and Oncology, Regional Blood Center, Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-4104-2296
Sociedade Brasileira de Oncologia Clínica · BRHemorio · BRUniversidade de São Paulo · BRUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sickle cell disease (SCD) is a group of hereditary chronic diseases with a substantial impact on quality of life and morbimortality. In Brazil, it is 1 of the most common hereditary diseases; however, there are sparse epidemiological data for the country. Using data from death certificates, we aimed to estimate the median age at death, years of life lost because of SCD, and the median survival. From 2015 to 2019, we identified 3320 records of deaths of individuals with SCD, from a total of 6 553 132 death records. Among individuals with SCD, the median age at death was 37 years less than that of the general population (SCD: aged 32.0 years at death, interquartile range [IQR], 19.0-46.0; general population: aged 69.0 years at death; IQR, 53.0-81.0). Results were consistent when stratified by sex or race. Over the 5 years evaluated, crude death rates varied from 0.30 to 0.34 per 100 000 inhabitants (mean 0.32 per 100 000 inhabitants). We estimated a prevalence of 60 017 individuals living with SCD (29.02 cases per 100 000) and an average incidence of 1362 cases yearly. The median estimated survival was 40 years for individuals with SCD and 80 years for the general population. SCD was associated with an increased risk of mortality in most age ranges. Among individuals with SCD aged between 1 and 9 years and between 10 and 39 years, the risk of death was 32 and 13 times higher, respectively. The most common causes of death were sepsis and respiratory failure. These results highlight the burden of SCD in Brazil and the necessity of improved care for this population.

Indexed as

Anemia, Sickle CellQuality of LifeBrazilChildChild, PreschoolHumansIncidenceInfantPrevalence

Identifiers

PMID37104056
PMCPMC10393747
OpenAlexW4367174068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.